Amid the COVID-19 pandemic, Val Sheffield is pivoting his research focus to find a way to test patients without using high demand cotton swabs.

University of Iowa Molecular Genetics Chair in the Carver College of Medicine Val Sheffield has made research breakthroughs in linking gene research and was recently named to a prestigious American research institutes class of 2020.

But amid the COVID-19 pandemic, Sheffield is pivoting his work to research an alternate way to test patients for novel coronavirus to alleviate a nationwide shortage of the parts in a COVID-19 test.

Sheffield and his team submitted a document April 1 to the FDA requesting emergency-use authorization to utilize a patient-sample collection method for COVID-19 testing.

My laboratory decided early on that we have the capability to help with [COVID-19] testing, Sheffield said. Testing is really important, but its behind where it should be because there arent enough official, FDA-approved swabs to collect samples from patients For the last month weve been trying to get FDA approval for our testing method where patients snort through the nose and spit into a tube, and the saliva sample is tested for the virus.

When the method is approved by the FDA, Sheffield said researchers can use it to test anyone. The most common coronavirus tests involve inserting a long cotton swab into a patients nostril. Sheffield anticipates beginning testing soon, with a limited number of patients in a study that will be the final step in getting FDA approval.

Iowa Gov. Kim Reynolds launched Test Iowa, a partnership between the state and private technology companies Domo, Qualtrics, and NomiHealth. But, the Test Iowa equipment was pending certification by the State Hygienic Lab to run tests as of Friday.

In Iowa, tests are being prioritized for those over the age of 60, with chronic health conditions, are in the hospital, or live in congregate living facilities such as a nursing home.

Iowa has tested more than 63,000 people and reported more than 10,000 cases as of Wednesday. Reynolds is using widespread testing as a signal that the state can begin the steps of reopening, seemingly going against the advice of University of Iowa researchers, who concluded that a second wave of COVID-19 cases could emerge without precautions in place.

In late April, amid his shifting work, Sheffield was elected to the 2020 class of the American Academy of Arts and Sciences.

Sheffield began as a faculty member at the UI 30 years ago and contributes to campus clinical work and research. He started as an assistant professor and has since branched out to administrative work, instruction, and research. He served as the UI Division Director of Medical Genetics for 22 years and stepped down in January to spend more time on research.

RELATED: National registrar association awards Sarah Harris with honorary membership after 30 years at UI

Sheffield has co-authored 330 peer-reviewed scientific papers, and said he has found supportive and outstanding collaborators who have been pivotal to his researchs success in his time at the UI.

My research focuses on hereditary blindness, he said. Ive worked on identifying genes that play a role in hereditary blindness. More recently, my team and I have been focusing on figuring out mechanisms by which mutations cause disease and developing treatments.

Sheffield said that his election has reinforced his obligation to serve and help others with his science. This will continue to fuel his desire to work hard and continue to further his research, Sheffield said.

David Ginsburg, James V. Neel Distinguished university professor at the University of Michigan Medical School, is also a member of the American Academy of Arts and Sciences. He first met Sheffield at the Howard Hughes Medical Institution.

Ginsburg said Sheffields research has been crucial to developing human genetic maps. Only a few academic scientists are elected to the U.S. organization a year, and Ginsburg said Sheffields election was well deserved.

Val is a fantastic physician scientist, Ginsburg said. Hes done landmark work figuring out what gene is defective for a whole variety of different, rare genetic diseases. He was one of the real pioneers tracking down these genes. He identified where the corresponding disease gene is located in our chromosomes for about 35 diseases When I was in medical school, we only knew the responsible gene for one human disease Today, we know the gene for about 6,000 human diseases, and Val was one of the early leaders in this work.

Ginsburg said he has seen how much members of the organization can grow once theyre inducted. Sheffield will be able to continue expanding his horizons in academia when he is inducted next spring, he added.

A big part of what drives what we do in academic medicine is interaction with colleagues and the new ideas that you get when meeting, talking, and interacting with colleagues in diverse fields, he said. Thats one of the greatest things the American Academy has to offer. I know it will give Val an opportunity to expand his research and intellectual contributions to the academic enterprise.

According to the American Academy of Arts and Sciences website, the 240-year-old American Academy of Arts and Sciences was founded by John Adams and John Hancock and aims to recognize scholars and leaders in various disciplines. Sheffield joins 11 other Hawkeyes already in the organization, including UI Cardiovascular Research Chair and Professor Francois Abboud.

Abboud said Sheffield, who he has known since 1990, is an internationally recognized leader in the field of human molecular genetics and genomics as well as someone he admires.

[Sheffield] is more than a great scientist, Abboud said. Ive always been impressed by his true commitment to his patients. What drives his scientific research is his extraordinary commitment to the patients. Science is his true passion. He is a brilliant scientist and an even more remarkable person.

Read this article:
University of Iowa molecular genetics researcher studying COVID-19 testing methods to alleviate test shortages - UI The Daily Iowan

Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image: National Institute of Allergy and Infectious Diseases, Flickr

For the sake of both science and action in the COVID-19 pandemic, we need collaboration among specialists, not sects.

The Brazilian-British biologist Peter Medawar won the Nobel Prize in 1960 for his study of acquired immune tolerance. Beyond his scientific work, he was also a gifted writer and expositor of scientific culture. One of the many treasures of his Advice to a Young Scientist (1979) is a passage in his chapter on Aspects of Scientific Life and Manners where he discusses techniques used in the hope of enlarging ones reputation as a scientist or diminishing the reputation of others by nonscientific means.

One such trick, Medawar writes, is to affect the possession of a mind so finely critical that no evidence is ever quite good enough (I am not very happy about. . . .; I must say I am not at all convinced by. . . .). After all, as he writes in a different passage, no hypothesis in science and no scientific theory ever achieves . . . a degree of certainty beyond the reach of criticism or the possibility of modification.

Scientists must resist the temptation to excessive skepticism: the kind that says no evidence is ever quite good enough. Instead they should keep their eyes open for any kind of information that can help them solve problems.

I share Medawars pragmatic vision of scientific reasoning. Scientists must resist the temptation to excessive skepticism: the kind that says no evidence is ever quite good enough. Instead they should keep their eyes open for any kind of information that can help them solve problems. Deciding, on principle, to reject some kinds of information outright, or to consider only particular kinds of studies, is counterproductive. Instead of succumbing to what Medawar calls habitual disbelief, the scientist should pursue all possible inputs that can sharpen ones understanding, test ones preconceptions, suggest novel hypotheses, and identify previously unrecognized inconsistencies and limitations in ones view of a problem.

This conception of science leads me to disagree with some elements of the philosopher of medicine Jonathan Fullers recent essay about two sects within epidemiology, defined by what kinds of evidence they consider meaningful and how they think decisions should be made when evidence is uncertain. Fuller sees in the contrast two competing philosophies of scientific practice. One, he says, is characteristic of public health epidemiologists like me, who are methodologically liberal and pragmatic and use models and diverse sources of data. The other, he explains, is characteristic of clinical epidemiologists like Stanfords John Ioannidis, who draw on a tradition of skepticism about medical interventions in the literature of what has been known since the 1980s as evidence-based medicine, privilege gold standard evidence from randomized controlled trials (as opposed to mere data), and counsel inaction until a certain ideal form of evidenceEvidence with a capital Ejustifies intervening.

Fuller rightly points out that this distinction is only a rough approximation; indeed, there are many clinical epidemiologists who do not share the hardline skepticism associated with the most extreme wing of the evidence-based medicine community. But the distinction is also misleading in a subtle way. If the COVID-19 crisis has revealed two competing ways of thinking in distinct scientific traditions, it is not between two philosophies of science or two philosophies of evidence so much as between two philosophies of action.

If the COVID-19 crisis has revealed two competing ways of thinking, it is not between two philosophies of science or two philosophies of evidence so much as between two philosophies of action.

In March, as health systems in Wuhan, Iran, and Northern Italy teetered under the weight of COVID-19 cases, Ioannidis cautioned that we really didnt know enough to say whether a response was appropriate, warning of a once-in a-century evidence fiasco and suggesting that the epidemic might dissipate on its own. (I replied to that argument, explaining why we do know enough to act decisively against this pandemic.) To my knowledge, Ioannidis has never stated that early interventions should have been avoided, but by repeatedly criticizing the evidence on which they were based, he gives that impression.

On the question of how we interpret evidence, Fuller concludes that to understand the scientific disagreements being aired about COVID-19, we need to blend the insights of each camp. Cooperation in society should be matched by cooperation across disciplinary divides, he writes. I dont understand what this kind of bothsidesism means when one side is characterized as accepting many types of evidence and the other as insisting on only certain kinds. On the question of how we should make decisions under uncertainty, of course more data are better. But decisions are urgent and must be made with the evidence weve got.

This is not to deny that there are different and valuable perspectives on epidemiology. Like any other field, there are many specialties and subspecialties. They have different methods for how they study the world, how they analyze data, and how they filter new information. No one person can keep up with the flood of scientific information in even one field, and specialization is necessary for progress: different scientists need to use different approaches given their skills, interests, and resources. But specialization should not lead to sectsin this case, a group of scientists who accept only certain kinds of evidence and too rigidly adhere to a philosophy of non-interventionism.

Infectious disease epidemiologists must embrace diverse forms of evidence by the very nature of their subject. We study a wide range of questions: how and under what conditions infectious diseases are transmitted, how pathogens change genetically as they spread among populations and across regions, how those changes affect our health, and how our immune systems protect us and, sometimes, make us vulnerable to severe illness when immune responses get out of control. We also seek to understand what kinds of control measures are most effective in limiting transmission. To understand these issues for even one type of diseasesay, coronavirus diseasesrequires drawing on a wide range of methodologies and disciplines.

On the question of how we should make decisions under uncertainty, of course more data are better. But decisions are urgent and must be made with the evidence weve got.

We consider evidence from classical epidemiological studies of transmission in households and other settings. We consider immunological studies that show us how markers of immunity develop, whether they protect us against future disease, and how particular markers (say a certain type of antibody directed at a certain part of the virus) change infection and mortality rates. We consider molecular genetics experiments, including those conducted in animal models, that tell us how changes in a viruss genome affect the course of disease. We consider evolutionary patterns in the viruss genetic code, seasonal patterns in its transmission and that of other related viruses, and observational studies of the risk factors and circumstances favoring transmission. And, of course, we also consider randomized trials of treatments and prevention measures, when they exist, as we seek to understand which interventions work and which ones may do more harm than good.

The upshot is that, done well, epidemiology synthesizes many branches of science using many methods, approaches, and forms of evidence. No one can be expert in all of these specialties, and few can even be conversant in all of them. But a scientist should be open to learning about all of these kinds of evidence and more.

Thinking about evidence from diverse specialties is critical not only for weighing evidence and deciding how to act but also for developing hypotheses that, when tested, can shed light across specialties. Appropriate humility dictates that molecular virologists should not assume they are experts in social epidemiology, and vice versa. To say Im a virologist, so Im not going to account for any findings from social epidemiology in my work gives up the chance to understand the world better.

Heres an example. In the case of a new virus like SARS-CoV-2, the fact that socioeconomically disadvantaged people get sick more often than the wealthy gives clues, which we dont yet know how to interpret, about the way the virus interacts with hosts. It would be informative to a virologist to distinguish the following two hypotheses (among others): (a) exposure to high doses of virus tends to cause severe disease, and disadvantaged people are often exposed to higher doses due to confined living and working conditions, or (b) comorbidities such as heart disease and obesity are higher among disadvantaged people, and lead to more severe outcomes. Of course, either, both, or neither of these hypotheses may turn out to be important explanations, but the canny virologist should wonder and think about how to distinguish them experimentally and test results against data from human populations. Reciprocally, a canny social epidemiologist should look to virological studies for clues about why COVID-19, like so many other illnesses, disproportionately harms the least advantaged in our society.

Done well, epidemiology synthesizes many branches of science. No one can be expert in all of these specialties, and few can even be conversant in all of them, but a scientist should be open to learning about all of these kinds of evidenceand more.

In practice, virologists, immunologists, and epidemiologists are different specialists who often work far apart and almost never attend each others seminars. I do not think we should spend all our time learning each others disciplines. But I do think that a scientist who genuinely wants to solve an important problem should be open to evidence from many sources, should welcome the opportunity to expand their list of hypotheses, and should seek to increase their chances both of making a novel contribution to their field and of being right. Central to this effort is considering information from diverse kinds of studies performed by people with diverse job titles in diverse departments of the universityas well as their diverse forms of data and argumentation.

When we move from the realm of understanding to the realm of intervention, the need for openness to different sources of evidence grows further. In some cases, like whether to use a drug to treat infection or whether to use a mask to prevent transmission, we can draw on evidence from experiments, sometimes even randomized, controlled, double-blind experiments. But in deciding whether to impose social distancing during an outbreak of a novel pathogenand in thinking about how the course of the epidemic might play outit would be crazy not to consider whatever data we can, including from mathematical models and from other epidemics throughout history. With infectious diseases, especially new and fast-spreading pandemics, action cant wait for the degree of evidentiary purity we get from fully randomized and controlled experiments, or from the ideal observational study. At the same time, we must continue to improve our understanding while we act and change our actions as our knowledge changesleaving both our beliefs and our actions open, as Medawar says, to the reach of criticism and the possibility of modification.

Where does the skepticism so characteristic of the evidence-based tradition come from? One reason may be the habits and heuristics we absorb from textbooks, colleagues, and mentors.

In supervising students and postdocs, inculcating these habits is one of the most challenging, gratifying, and time-consuming parts of scientific trainingfar more than teaching technical skills. Some of these rules of thumb are well suited to science in general and serve us well throughout our careers, no matter the field. Among these are workaday but important heuristics like: consider alternative hypotheses; look at raw data whenever possible before looking at processed data; and repeat experiments, especially those whose results surprise you. Indeed, these heuristics can be summarized as a form of intense skepticism directed at ones own work and that of ones team: find all the flaws you can before someone else does; fix those you can and highlight as limitations those which are unfixable. Recently an advanced PhD student said to me: I read your new idea that you shared on Slack this morning and Ive been doing my best all afternoon to break it. It made my day, and made me think I probably had very little left to teach her.

Scientists of all stripes should work together to improve public health, and none should mistake a professional tendency or a specialists rule of thumb for an unshakable epistemological principle.

Other heuristics, however, are more specific to a narrow field and may be ill suited to other contexts. Insisting on gold standard, randomized trial evidence before prescribing drugs to prevent heart attacks or before performing a certain surgical operation may be a good rule of thumb in medicine (though not all physicians or even philosophers agree). But randomized controlled trials are not available for huge swaths of scientific inquiry, and the narrow populations often studied in such trials can limit their applicability to real-world decision making. Nor are they always available when we need them: they require a lot of time and administrative resources to execute (and money, for that matter). Stumping for Evidence is thus useful in many parts of clinical medicine but impractical in many other aspects of science-informed decision making. Applying this doctrine indiscriminately across all areas of science turns the tools of a specialist into the weapons of a sectarian.

This point was appreciated by some of the pioneers of evidence-based medicine: David Sackett, William Rosenberg, J. A. Muir Gray, R. Brian Haynes, and W. Scott Richardson. Evidence-based medicine is not restricted to randomized trials and meta-analyses, they wrote in 1996. It involves tracking down the best external evidence with which to answer our clinical questions. And last week the Oxford professor of primary care Trisha Greenhalgh, another major contributor to this field and author of a popular textbook on evidence-based medicine, suggested that in the realm of social interventions to control the spread of COVID-19, the evidence-based clinical paradigmwaiting for the definitive [randomized controlled trial] before taking actionshould not be seen as inviolable, or as always defining good science.

Indeed, on the question of how we ought to act during an outbreak, two leading epidemiologists in the clinical tradition, Hans-Olov Adami and the late Dimitrios Trichopoulos, argued that the non-interventionist rule of thumb is suitable for chronic, noncommunicable diseases but foolish for fast-moving infectious diseases. In an editorial accompanying an article that showed that the impact of cell phones in causing brain cancer was not large but might be larger than zero, they counseled cautious inaction in regulating cell phones. But they noted this is not how you would reason in the case of a transmissible disease:

There is another lesson to be learned about the alarms that have been sounded about public health during the past few years. When the real or presumed risk involves communicable agents, such as the prions that cause bovine spongiform encephalopathy (mad cow disease), no precaution, however extreme, can be considered excessive. By contrast, for noncommunicable agents, such as radio-frequency energy, the lack of a theoretical foundation and the absence of empirical evidence of a substantial increase in risk legitimize cautious inaction, unless and until a small excess risk is firmly documented.

In my ideal public health world wed have a lot more good sense like that proposed by Adami and Trichopoulos, acting not only on the strength of the evidence we have but on the relative harms of being wrong in each direction. And whether waiting or acting, wed work hard to get the evidence to meet the challenges of skeptics and improve our decision-making, all with an eye to the possibility of criticism and modification Medawar describes.

See the original post here:
Good Science Is Good Science - Boston Review